These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28522279)

  • 41. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
    Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
    Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
    Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
    Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy - a single-centre experience.
    Henkenberens C; Janssen S; Lavae-Mokhtari M; Leni K; Meyer A; Christiansen H; Bremer M; Dickgreber N
    Radiat Oncol; 2016 Feb; 11():12. PubMed ID: 26830686
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
    Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcomes of single dose stereotactic radiotherapy for lung metastases.
    Osti MF; Carnevale A; Valeriani M; De Sanctis V; Minniti G; Cortesi E; Martelli M; Maurizi Enrici R
    Clin Lung Cancer; 2013 Nov; 14(6):699-703. PubMed ID: 23886798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
    Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.
    Nakamura M; Nishimura H; Nakayama M; Mayahara H; Uezono H; Harada A; Hashimoto N; Ejima Y; Ishihara T; Sasaki R
    Br J Radiol; 2016 Dec; 89(1068):20160560. PubMed ID: 27805837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Computed Tomography-Guided Interstitial High-Dose-Rate Brachytherapy in Combination With Regional Positive Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: A Phase 1 Clinical Trial.
    Xiang L; Zhang JW; Lin S; Luo HQ; Wen QL; He LJ; Shang CL; Ren PR; Yang HR; Pang HW; Yang B; He HL; Chen Y; Wu JB
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1027-1034. PubMed ID: 26194678
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer.
    Henderson M; McGarry R; Yiannoutsos C; Fakiris A; Hoopes D; Williams M; Timmerman R
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):404-9. PubMed ID: 18394819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience.
    Stephans KL; Djemil T; Reddy CA; Gajdos SM; Kolar M; Mason D; Murthy S; Rice TW; Mazzone P; Machuzak M; Mekhail T; Videtic GM
    J Thorac Oncol; 2009 Aug; 4(8):976-82. PubMed ID: 19633473
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer.
    Videtic GM; Stephans KL; Woody NM; Reddy CA; Zhuang T; Magnelli A; Djemil T
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):203-8. PubMed ID: 25015198
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypofractionated stereotactic radiotherapy with or without whole-brain radiotherapy for patients with newly diagnosed brain metastases from non-small cell lung cancer.
    Ma LH; Li G; Zhang HW; Wang ZY; Dang J; Zhang S; Yao L; Zhang XM
    J Neurosurg; 2012 Dec; 117 Suppl():49-56. PubMed ID: 23205789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
    Rosenzweig KE; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling CC; Armstrong J; Ginsberg R; Kris MG; Raben A; Leibel S
    Cancer J; 2000; 6(2):82-7. PubMed ID: 11069224
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Posttreatment Immune Parameters Predict Cancer Control and Pneumonitis in Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
    Zheng Y; Shi A; Wang W; Yu H; Yu R; Li D; Xu B; Ma H; You J; Zhao D; Jiang L; Geng J; Zhu G
    Clin Lung Cancer; 2018 Jul; 19(4):e399-e404. PubMed ID: 29519614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
    Bradley JD; El Naqa I; Drzymala RE; Trovo M; Jones G; Denning MD
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1146-50. PubMed ID: 19800181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical outcomes of stereotactic radiotherapy for stage I non-small cell lung cancer using a novel irradiation technique: patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner.
    Onishi H; Kuriyama K; Komiyama T; Tanaka S; Sano N; Marino K; Ikenaga S; Araki T; Uematsu M
    Lung Cancer; 2004 Jul; 45(1):45-55. PubMed ID: 15196734
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation.
    Binkley MS; Hiniker SM; Chaudhuri A; Maxim PG; Diehn M; Loo BW; Shultz DB
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):808-15. PubMed ID: 26831903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.